2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - New Orleans Theatre A
Technology and Procedures, Assays, Imaging, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Biological Therapies, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

398 Microenvironmental adaptation selects intrinsically plastic MYC+ and BCL6+ cell states during lymphoma progression from germinal centers

Zhangliang Cheng, BSc, Song Wu, PhD2, Ruoyi Shi3, Kohei Kume, PhD4, Mark E Robinson, PhD5, Richard Kim6, Mina L Xu, MD7, Markus Müschen, MD-PhD8
1 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Immunobiology, New Haven, Connecticut, United States
2 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
3 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
4 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
5 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
6 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
7 Department of Pathology, New Haven, Connecticut, United States
8 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Immunobiology, New Haven, Connecticut, United States

Background and Significance. During normal germinal-center (GC) reactions, B cells alternate between MYC+ light zone (LZ) and BCL6+ dark zone (DZ) states in response to microenvironmental cues. LZ T-follicular helper cells and follicular dendritic cells induce MYC to promote biomass accumulation and anabolic growth. Following migration into the nutrient-limited DZ, B cells transition to a BCL6+ DZ state that protects against excessive DNA damage.

Results. Multiplex immunofluorescence of reactive tonsils, low- and high-grade follicular lymphoma, GCB-DLBCL, and ABC-DLBCL demonstrated progressive expansion of MYC-stage cells with disease progression, while MYC+ and BCL6+ cells remained spatially segregated. Despite complete loss of GC architecture during lymphoma progression, we found that spatial segregation of MYC+ and BCL6+ cells was remarkably preserved, suggesting that environmentally instructed cell-state organization persists during malignant transformation. This organization was confirmed in independent spatially resolved datasets. Single-cell spatial transcriptomics combined with MYC/BCL6 protein imaging demonstrated that these populations represent alternative transcriptional states rather than genetically distinct lymphoma subclones. MYC+ cells were enriched for MYC targets, mTORC1, and TNFα/NF-κB signaling, whereas BCL6+ cells preferentially activated autophagy, FOXO1, and mitotic programs, consistent with a resource-conserving proliferative state.

Spatial ligand-receptor analysis showed that lymphoma cells respond to local microenvironmental signals according to regulatory principles resembling those of the normal GC. MYC+ cells preferentially occupied supportive niches enriched for VCAM1-, ICAM1-, and CD44-signaling, whereas BCL6+ cells localized to inhibitory niches enriched for ST6GAL1-CD22 interactions. Although these programs were largely preserved during transformation, their cellular sources shifted from T-follicular helper cells and follicular dendritic cells in reactive tonsils to tumor-associated macrophages and exhausted CD8 T cells in lymphoma. Thus, lymphoma adapts to newly established immune niches while maintaining conserved MYC-BCL6 state regulation.

To test whether MYC-BCL6 plasticity is intrinsic to lymphoma cells, we generated endogenous MYC-dTAG-mNeonGreen/BCL6-mScarlet dual-reporter ABC- and GCB-DLBCL models by CRISPR knock-in. Long-term live-cell imaging revealed spontaneous transitions between MYC+ and BCL6+ states within individual cells under constant culture conditions. RNA sequencing of reporter-sorted populations recapitulated the transcriptional programs observed in patient tissues, validating these models for mechanistic studies.

To identify regulators of MYC↔BCL6 transitions, we performed genome-wide CRISPR screens in dual-reporter DLBCL models. We transduced 160 million cells at 40% efficiency with the human Brunello library. After eight days, the top 1% of MYC-mNeonGreen+ and BCL6-mScarlet+ cells were isolated for sequencing.

CRISPR screens in DLBCL cells identified FBXO11 and FBXW7 as selective, reciprocal posttranslational regulators of BCL6 and MYC. Both function as substrate-recognition subunits of SCF E3 ubiquitin ligases: FBXO11 initiates BCL6 degradation, whereas FBXW7 drives MYC degradation. Their identification in DLBCL, together with their ability to mediate protein degradation within one hour, implicates them in rapid MYC↔BCL6 transitions occurring with approximately four-hour periodicity.

Consistent with CD40 signaling as a determinant of MYC+ LZ GC B cells, CRISPR screens identified CD40 and its downstream components TRAF6 and RELA, together with the TLR adaptor MYD88, as requirements for transition toward the MYC state through NF-κB signaling. Conversely, FOXO1 and GSK3B, a key initiator of MYC degradation, emerged as candidate mediators of the transition from MYC to BCL6.

Conclusions. These findings establish MYC↔BCL6 plasticity as an intrinsic property of GC-derived lymphoma cells, while the tumor microenvironment spatially selects these states. Beyond subclonal diversification, lymphoma maintains phenotypic heterogeneity by adapting intrinsically plastic cells to local immune niches. This work provides a mechanistic framework for lymphoma heterogeneity and supports therapeutic strategies that simultaneously target complementary MYC- and BCL6-associated states and their instructive microenvironments.

Zhangliang Cheng, BSc: No relevant conflicts of interest to declare.